AZN AstraZeneca PLC

$AZN this somehow boring stock that I’m starting to think the market has forgotten it's trading at 20% discount right now. With oncology making up nearly half of the revenue and a deep pipeline across lung, breast, liver and other cancers, the next few oncology conferences could get interesting. ESMO is coming up in October, and AZN is hosting a dedicated investor event there. Sometimes the “boring” mega-cap pharma is exactly where you want to be before the catalyst cycle starts. AZN could be a lot less boring by year-end.

$AZN forget you guys, IDGAF. we are lakost there fam. Give me a little more 🚀 juice so i can shove it up Cramer’s a55.

$AZN why not best the $1.5 billion $PSNL buyout? Offer $3 billion, buy a key genetic sequencing engine and involvement in the $MRNA melanoma vaccine

$AZN I will Let you in on a secret. Check out CADL and can-2409 and can-3110 . It’s early but they have something special for the breast cancer

AstraZeneca said its breast cancer drug Etcamah failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial, sending its U.S.-listed shares down about 3% in after-hours trading. The trial evaluated Etcamah in combination with palbociclib in previously untreated patients with advanced breast cancer. While the combination showed a numerical improvement in progression-free survival, it did not achieve the study’s primary goal, and AstraZeneca said it will provide the full trial results at a later date. The setback comes only a week after the FDA granted accelerated approval for Etcamah to be used alongside certain CDK4/6 inhibitors, a class of targeted cancer drugs. The failed trial could raise questions about the drug’s broader effectiveness in earlier-line treatment, although the company continues to have an approved use for the therapy under the FDA’s accelerated pathway. $AZN

$AZN Is there any news for the drop in stock price? I was able to sell 600 shares from on a gain from QQQI. Thank god I sold 9/18 $165 options yesterday for $2.05. this is going to take time and patience to exit.

$AZN In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new treatment paradigm for molecular-guided cancer care. The oral SERD, to be marketed as Etcamah, has been approved in combination with a CDK4/6 inhibitor for the treatment of HR-positive, HER2-negative breast cancer, but only upon detection of ESR1 mutation during initial first-line treatment with an aromatase inhibitor and a CDK4/6 drug. Etcamah survived a hesitant FDA and an overwhelming rejection by an advisory committee to secure Friday’s surprise approval.

$AZN ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial By Marissa Russo Aug 31, 2026 11:13am

$AZN AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be a breakthrough treatment for COPD and reach AstraZeneca’s peak annual sales forecast of more than $5 billion for the drug. The drug, tozorakimab, helped reduce flare-ups in a broad range of people with the condition.

$AZN recently raised its peak annual sales forecast for it's COPD drug to more than $5 billion, which could help the company reach its overall $80 billion revenue target by 2030. CEO Pascal Soriot said the drug has the opportunity to capture a broad group of patients. “believe it can be more than 5 billion, simply because the unmet need is huge,” Soriot said. “Patients are underdiagnosed; they need to be better diagnosed, and biologics in this class are totally underused.

$AZN Citi kept its buy rating and £178 target price on Astrazeneca. Citi said AstraZeneca remained undervalued, forecasting annual earnings growth of about 15% between 2027 and 2030 and pointing to what it called the strongest drug pipeline in the sector.

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus $AZN $PVAL $AVDE https://stocktwits.com/news/equity/markets/azn-stock-slips-after-hours-following-latest-late-stage-oncology-trial-miss-executive-disappointed-reiterates-breast-cancer-focus/cZtXD0GRBb0

$AZN down 10 % this year and up like 1.5 % one year, almost the same on 3 year (1.7 %). What will next report say about the future?

$AZN so this is the result after Dr. Marc Siegel on Fox News speaks about their breakthrough drugs... Hmmm

Cramer's lightning round: 'I am not going to put my money on AstraZeneca' $azn AstraZeneca: “I’m a little nervous about it. It’s been missing some of its trials. ... I am not going to put my money on AstraZeneca.” https://www.cnbc.com/2026/09/08/cramers-lightning-round-i-am-not-going-to-put-my-money-on-astrazeneca.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

$AZN One of the pharma compounders I like. I've spent some time digging into AstraZeneca and what stands out isn't one particular drug. It's the sheer depth of the pipeline and how quickly the business is continuing to grow. H1 2026 revenue was $30.7B, up 6%, while core EPS grew 11%. Oncology grew 15% and Rare Disease grew 11%. The pipeline is the real story: 183 projects, including 116 Phase II/III programs and 21 late-stage new molecular entities. AZN expects to launch at least 20 new medicines by 2030 and is targeting $80B of revenue by 2030, versus $58.7B in 2025. What I like is that growth isn't dependent on one blockbuster. AZN has multiple large franchises across oncology, rare disease, respiratory, cardiovascular and immunology, while continuously adding new products behind them. They can lose exclusivity on older drugs and still keep growing because there's another generation of medicines coming through the pipeline. A potentially very strong long-term compounder.